PUR 0110

Drug Profile

PUR 0110

Alternative Names: PCT-233; PUR-0110

Latest Information Update: 23 Jun 2015

Price : $50

At a glance

  • Originator PurGenesis Technologies
  • Class Anti-inflammatories
  • Mechanism of Action Antioxidants; Cytokine inhibitors; Interleukin 10 modulators; Reactive oxygen species inhibitors; Tumour necrosis factor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Preclinical Psoriasis

Most Recent Events

  • 23 Jun 2015 Phase-II development is ongoing for Ulcerative colitis
  • 06 Aug 2013 Adverse events and pharmacodynamics data from a phase IIa trial in Ulcerative colitis released by PurGenesis Technologies
  • 10 Jun 2010 Phase-II clinical trials in Ulcerative colitis in Germany (Rectal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top